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for identification and evaluation of acute-
phase of infective and non-infective inflam-
mation reactions (Jaye and Waites, 1997).  In 
virtually all acute bacterial infections, respira-
tory diseases, some tumors and various types 
of tissue destruction, myocardiac infarction 
inclusive, the CRP rises (Roivainen et al., 
2000).  Another non-specific test to monitor 
inflammation is erythrocyte sedimentation 
rate (ESR). Both are elevated in the presence 
of inflammation, although, CRP appears and 
then disappears sooner than change in the 
ESR.  The CRP level may fall to normal if 
treatment is successful but the ESR may still 
be abnormal for a longer period (Meier-
Ewert et al., 2001). 
 
C-reactive protein is an acute-phase plasma 
protein produced by the liver that rapidly 
change in concentration in the plasma in re-
ABSTRACT 
This study was conducted to evaluate c-reactive proteins on some inflammatory diseases among indi-
viduals aged 1 year and above attending out-patient clinic and emergency units of three hospitals in 
Abeokuta in southwestern Nigeria.  Of the 266 blood samples examined overall, the CRP value was 
highest (16.7%) among age group 31-40 years and there was significant difference between CRP 
value and age groups (p=0.0060).  More males (18%) had high CRP than female (16%), however 
there was no significant difference between the CRP values and sex.  C-reactive protein was signifi-
cantly high among the patients with anaemia (p<0.0001. r = -0.376).  Of the patients with high CRP, all 
had significantly elevated erythrocyte sedimentation rate (p<0.0001).  There was significant difference 
between CRP and both urea and creatinine (P<0.0001).  There was association between CRP and 
cholesterol with X2 value of 59.484 and significant at less than 1%. 
INTRODUCTION 
The C-reactive protein (CRP) was first rec-
ognized at Rockefeller University as a con-
stituent in the serum of patients with acute 
pneumonia that formed a precipitation reac-
tion with the C-mucopolysaccharide of cer-
tain groups of pneumococci and also gives 
the capsular swelling reaction when mixed 
with whole organisms (Tillet and Francis, 
1930).  In the serum it is present in the 
form of a glycoprotein complex which trav-
els in the alpha-globulin region.  Isolation 
and crystalized material had been injected 
into animals and an antibody raised against 
it which forms the basis of most laboratory 
methods of demonstrating its presence in 
patients (McCarty, 1947). 
 
C-reactive protein has long been known as 
non-specific but constitutes optimal marker 
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sponse to a variety of stimuli most notably 
inflammation and tissue injury.  When in-
flammation occurs there is a rapid rise in 
CRP levels, usually proportional to the de-
gree of immunological stimulation and 
when inflammation resolves the CRP rap-
idly falls and therefore CRP level represents 
a good marker for disease activity and se-
verity (Pepys and Hirschfield, 2003; Coven-
try et al., 2009).  Reports have showed a very 
significant positive correlation between 
CRP levels and cardiovascular diseases 
(Gracia-Moll et al., 2000; Pasceri et al., 2000; 
Ridker et al., 2000) and between CRP levels 
and the extent of the arterosclherotic dis-
eases (Pepys and Hirschfield, 2003).  Higher 
rate of cardiovascular diseases have been 
associated with human immunodeficiency 
virus due to inflammation activated by im-
mune system and results in a proinflamma-
tory state leading to elevated CRP level 
(Reingold et al., 2008). 
 
CRP production is part of the specific and 
nonspecific acute phase response to most 
forms of inflammation, infection and tissue 
damage.  The CRP blood level and other 
blood parameters would be useful tools in 
diagnosis and possibly to the physicians to 
monitor therapeutic response to treatment 
in some inflammatory diseases.  This study 
therefore examines the CRP levels among 
patients routinely attending out-patient clin-
ics. 
 
MATERIALS AND METHODS 
Study Area 
The study was conducted in Abeokuta the 
capital city of Ogun State Southwestern Ni-
geria from October 2009 to April 2010 
among patients at the out-patient and emer-
gency unit at the Federal Medical Centre, 
Idi-Aba, State General Hospital, Ijaiye and 
Olikoye Ransome-Kuti Memorial Hospital 
at Asero, Abeokuta.  The ethical approval 
was granted by the Ethical Committees of 
the hospitals. 
Two hundred and sixty-six (266) samples 
were collected for this study.  Venous blood 
samples were obtained from each patient 
into ethylediamine tetraacetate (EDTA) anti-
coagulated and non-anticoagulated tubes.  
The non-anticoagulated tubes were centri-
fuged at 2000 revolution per minute (rpm) 
for 5 minutes to obtain serum stored at 20oC 
for serologic and biochemical analysis. 
 
Haematocrit and Erythrocyte Sedimenta-
tion Rate Determination 
The haematocrit (Hct) which is known as the 
packed cell volume (PCV) of each patient 
was determined by centrifugation of EDTA 
anti-coagulated blood in heparinized capil-
lary tubes (with the end sealed) using Hawsk-
ley haematocrit centrifuge.  The erythrocyte 
sedimentation rate (ESR) of each patient was 
determined by Westergreen-micro method 
using EDTA anticoagulated blood and the 
reading was taken at the end of one hour. 
 
Serologic Analysis 
The HIV-1 and HIV-2 screening kit used in 
this study was SD Bioline standard Diagnos-
tic Inc. (Korea).  This is immunochroma-
tographic (rapid) method for quantitative 
detection of antibodies of all isotopes (IgG, 
IgM, IgA) specific to HIV-1 and HIV-2 si-
multaneously in serum, plasma or whole 
blood.  This method used for each patient 
serum is highly sensitive and specific with 
very suitable control system incorporated. 
 
The CRP reagent kit used was manufactured 
by Cypress Diagnostics, Belgium.  The CRP 
reagent is a suspension of positive latex par-
ticle coated with the gamma globulin fraction 
of anti human CRP specific serum.  When 
CRP is present in the sample, the resulting 
1*D.A. OJO AND 2O.A. TALABI 
J. Nat. Sci. Engr. Tech. 2010, 9(1):106-114 107 
turbidity was measured colorimetrically at 
340nm.  The CRP in each sample is then 
calculated using a standard CRP solution. 
 
Biochemical Analysis 
The cholesterol level was determined by 
spectrophotometric enzyme method using 
reagent kit of Randox Laboratories Ltd., 
Antrim, United Kingdom. Spectropho-
tometric analysis of urea and creatinine 
were carried out by the Oxime method and 
Jaffe reactions respectively (Bauer et al., 
1974). 
 
Data Analysis 
The study was carried out and the propor-
tion of individual CRP levels were calcu-
lated and level cross tabulated with age, sex, 
packed cell volume, erythrocyte sedimenta-
tion rate, human immunodeficiency virus 
infection, cholesterol, urea and creatinine 
using SPSS 11 windows packages.  Relevant 
chi-square and correlation statistics were 
computed using Pearson correlation coeffi-
cient models. 
 
RESULTS 
Two hundred and sixty-six individuals at-
tending out-patient clinics and emergency 
units were examined in this study as shown 
in Tables 1 and 2. 
 
Of this, 154 (57.9% were male while 112 
(42.1%) were female.  There were more pa-
tients in the 31 – 40 year-age group 108 
(40.6%) while fewer were seen in the 1 – 10 
year-age group 6 (2.3%).  Overall the CRP 
value was highest among the age group 31 – 
40 years 18 (16.7%). 
 
The chi-square statistics for the test of no 
association between age and C-reactive pro-
tein as shown in Table 1 had a value of 
28.00% and statistically significant at less 
than 1% level and thus null hypothesis of no 
association is rejected.  There was no signifi-
cant difference between sex and c-reactive 
protein (p= 0.8080),), however, more males 
had higher CRP values, 28 (18.2%) than fe-
males 18 (16.1%). 
 
In Table 3, of 104 patients with very high 
CRP values (>40mg/L), 36 (34.6%) had 
anaemia (Hct = 20 – 35%), 2 (1.9%) with 
moderately high CRP (11 – 40mg/L) and 66 
(63.5%) normal CRP (0 – 10mg/L).  The 
computed chi-square statistics for the test of 
no association between haematocrit and 
CRP levels had a value of 35.840 and is sig-
nificant at less than 1% level.  Thus the null 
hypothesis of no association is rejected. 
 
The cross tabulation between the ESR and 
CRP in Table 4 shows that 2 (1.3%) of pa-
tients with high CPR of 11 – 40mg/L and 
>40mg/L respectively had normal ESR (3 – 
8mm/h) while 44 (78.6%) patients with ex-
tremely elevated CRP (> 40mg/L) had ESR 
greater than 40mm/h.  There is significant 
difference between the ESR and CRP (p< 
0.0001).The cross-tabulation between serum 
urea/creatinine and CRP values of patients 
examined is presented in Table 5.  It shows 
that 32 (13.6%) of the patient with normal 
blood urea (15 – 38mg/L) and creatinine 
(0.9 – 1.5mg/dL) had highly elevated CRP 
(> 40mg/L) while 2 (21%) with moderate 
and highly elevated values had CRP greater 
> 40 mg/L.  The computed chi-square for 
the test of no association between blood 
urea/creatinine and CRP gave the same 
value of 43.816 and was statistically signifi-
cant at less than 1% level.  Thus the null hy-
pothesis of no association is rejected in each 
case. 
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Table 1: C - reactive protein Distribution by Age of the Patients 
Age (Years) Number ]
Examined (n) 
C-Reactive Protein (mg/L) 
0 – 10 
n (%) 
11 – 40 
n (%) 
> 40 
n (%) 
1 – 10 6 6 (100%) 0 (0%) 0 (0%) 
11 – 20 26 24 (92.3%) 0 (0%) 2 (7.7%) 
21 – 30 52 50 (96.2%) 0 (0%) 2 (3.8%) 
31 – 40 108 86 (79.6%) 4 (3.7%) 18 (16.7%) 
41 – 50 40 24 (60.0%) 2 (5.0%) 14 (35.0%) 
51 – 60 26 18 (69.2%) 0 (0%) 8 (30.8%) 
61 – 70 8 6 (75.0%) 0 (0%) 2 (25.0%) 
Total 266 214 (80.5%) 6 (2.3%) 46 (13.3%) 
Table 2:  C-reactive Protein Distribution by Sex of the Patients 
Sex Number  
Examined (n) 
C-Reactive Protein (mg/L) 
0 – 10 
n (%) 
11 – 40 
n (%) 
> 40 
n (%) 
Male 154 122 (79.2%) 4 (2.6%) 28 (18.2%) 
Female 112 92 (82.1%) 2 (1.8%) 18 (16.1%) 
Total 266 214 (80.5%) 6 (2.3%) 46 (17.3%) 
Table 3: Haematocrit Level in Relation to C - reactive protein  
PCV (%) Number  
Examined (n) 
C-Reactive Protein (mg/L) 
0 – 10 
n (%) 
11 – 40 
n (%) 
> 40 
n (%) 
35 – 54 162 148 (91.4%) 4 (2.5%) 10 (6.2%) 
20 - 34 104 66 (68.5%) 2 (1.9%) 36 (34.6%) 
Total 266 214 (80.5%) 6 (2.3%) 46 (17.3%) 
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Table 4: Frequency Distribution of Erythrocyte Sedimentation Rate in Relation 
to the C - reactive protein Level 
ESR (mm/h) Number  
Examined (n) 
C-Reactive Protein (mg/L) 
0 – 10 
n (%) 
11 – 40 
n (%) 
> 40 
n (%) 
3 – 8 152 148 (97.4%) 2 (1.3%) 2 (1.3%) 
9 – 40 58 54 (93.1%) 4 (6.9%) 0 (0%) 
> 40 56 12 (21.4%) 0 (0%) 44 (78.6%) 
Total 266 214 (80.5%) 6 (2.3%) 46 (17.3%) 
Table 5: Blood Urea and Creatinine of the patients in Relation to C-reactive  
               Protein 
Blood Urea 
Creatinine* 
(mg/dL) 
Number  
Examined (n) 
C-Reactive Protein (mg/L) 
0 – 10 
n (%) 
11 – 40 
n (%) 
> 40 
n (%) 
15 – 38 (0.9 – 15)* 236 200 (84.7%) 4 (1.7%) 32 (13.6%) 
29 – 60 (1.6 – 2.7)* 8 4 (50.0%) 2 (25.0%) 2 (25.0%) 
61 – 120 (2.8 – 6.0)* 22 10 (45.5%) 0 (0%) 12 (54.5%) 
Total 266 214 (80.5%) 6 (2.3%) 46 (17.3%) 
The cross-tabulation between the blood 
cholesterol and CRP values of the patients 
examined is shown in Table 6.  This table 
shows that 30 (12.2%) of the patient with 
normal blood cholesterol (140 – 200mg/
dL) had highly elevated CRP values             
(> 40mg/L) while 16 (80.0%) with elevated 
cholesterol values also had high CRP values.  
There is significant difference between the 
blood cholesterol and CRP values (P < 
0.0001). 
 
The human immunodeficiency virus infec-
tion in relation to the CRP level is shown in 
Table 7.  It shows that 16 (66.7%) of the pa-
tients with positive HIV infections had ele-
vated CRP values (> 40mg/L) while 30 
(12.4%) patients negative HIV infections had 
CRP values lesser than 40mg/L.  The chi-
square status computed for the test of no 
association between HIV infection and CRP 
level gave a value of 45.062 and significant at 
less than 1% level and thus the null hypothe-
sis of no association is rejected. 
 
Correlation analysis was carried out to      
examine the relationship between PCV, ESR,  
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Urea/Creatinine and cholesterol values with 
CRP values as shown in Table 8.  The out-
put from this analysis shows that there was 
positive, linear and significant relationship 
between each of these variables and CRP 
(<0.0001), the strength of association being 
99%.  However, a negative coefficient of -
0.376 for the relationship with PCV sug-
gesting that PCV was decreasing with a cor-
responding increasing CRP values. 
 
DISCUSSION  
This study showed that the CRP is highest 
in the age group 31 – 40 years among pa-
tient in Abeokuta metropolis.  This report 
corresponds with previous report studies 
(Pepys and Hirschfield, 2003; Zacho et al., 
2008; Cushman et al., 2009).  This may be 
attributed to coronary artery risk develop-
ment in young adults (Cushman et al., 2005; 
Reingold et al., 2008 and Cushman et al., 
2009).  There was no significant difference 
between sex and CRP, although more men 
have increased CRP than women in this 
investigation which is in contrast to the pre-
vious reports (Rider and Cook, 2004; Cush-
man et al., 2005; Cook et al., 2006; Ridker et 
al., 2007; Cushman et al., 2009).  The differ-
ence may be due to the various socio-
economic, geographical and ethnic groups 
in the study areas. 
 
In the report of Kanfer and Nicol (1997) 
which is similar to the finding in this study, 
increased CRP was significantly observed in 
patients that were anaemic (PCV = 20 – 
35%).  This observation also supports the 
reports of others (Pepys and Hirschfield, 
2003; John et al., 2004; Clyne and Jonathan, 
2009; Reingold et al., 2008).  In this study, 
increased CRP is observed in patients with 
extremely elevated erythrocyte sedimenta-
tion rate (ESR).  Previous reports (Brigden, 
1998; John et al., 2004; Cook et al., 2004) are 
in support of this finding that the levels of 
ESR and CRP are useful indicators for in-
flammatory reactions.  This shows that the 
level of inflammatory reaction is significantly 
high with increased CRP as excellent predic-
tive value than ESR.  Generally, elevated 
blood urea and creatinine are indicative of 
renal malfunction (Davidsohn and Henry, 
1974 and Brooks et al., 1998).  In this study, 
both blood urea and creatinine were elevated 
in patients with increased CRP which is indi-
cation of renal malfunction.  Also, this re-
port showed that there were associations be-
tween the CRP and cholesterol which is a 
heart index (arteriosclerosis).  This may be 
attributed to the effect of cholesterol and the 
lipoproteins involvement in immune re-
sponse and tissue repair as recorded by pre-
vious observations (Ridker et al., 2002; Rid-
ker, 2003; Cushman et al., 2009). 
 
CONCLUSION 
The result of this study showed significant 
increase in the CRP of the HIV positive pa-
tients which shows the level of inflammatory 
reaction.  This is in agreement with previous 
investigations (Lau et al., 2006 and Reingold 
et al., 2008).  This may have implications for 
cardiovascular diseases among HIV-infected 
patients (John et al., 2004; Lloyd-Jones et al., 
2006; Lau et al., 2006; Reingold et al., 2008).  
Future studies should evaluate carefully the 
epidemiology of CRP with cardiovascular 
diseases in HIV-infected persons.  Also, sev-
eral articles in other parts of the world have 
been published on relationship between CRP 
and cardiovascular diseases especially coro-
nary artery disease and therefore, future 
studies would have an important role in as-
sessing and treatment of these patients in 
this study area where most physicians are not 
aware of the importance of CRP as diagnos-
tic tool in inflammatory diseases. 
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Table 6: Total Blood Cholesterol and C - reactive protein 
Blood   
Cholesterol 
(mg/dL) 
Number  
Examined (n) 
C-Reactive Protein (mg/L) 
0 – 10 
n (%) 
11 – 40 
n (%) 
> 40 
n (%) 
140 – 250 246 210 (85.4%) 6 (2.4%) 30 (12.2%) 
> 250 20 4 (20.0%) 0 (0%) 16 (80.0%) 
Total 266 214 (80.5%) 6 (2.3%) 46 (17.3%) 
Table 7: Human Immunodeficiency virus Infection in the Patients  
    and C-reactive Protein 
HIV Infection Number  
Examined (n) 
C-Reactive Protein (mg/L) 
0 – 10 
N (%) 
11 – 40 
n (%) 
> 40 
n (%) 
Positive 24 8 (33.3%) 0 (0%) 16 (66.7%) 
Negative 242 206 (85.1%) 6 (2.5%) 30 (12.4%) 
Total 266 214 (80.5%) 6 (2.3%) 46 (17.3%) 
Table 8: Correlation Coefficients between CRP with PCV, ESR, Urea/ 
               Creatinine and Cholesterol 
Variables Correlation  
Coefficient (R) 
R Square Std. Error P Value 
PCV/CRP -0.376 0.141 4.7973 <0.0001 
ESR/CRP 0.723 0.522 21.774 <0.0001 
Urea and Creatinine/CRP 0.283 0.080 15.3437 <0.0001 
Cholesterol/CRP 0.375 0.140 32.5014 <0.0001 
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